Advice
following a full submission:
zuranolone (Zurzuvae®) is not recommended for use within NHSScotland.
Indication under review: treatment of moderate or severe postnatal depression (PND) in adults following childbirth.
In a double-blind, phase III study, zuranolone, compared with placebo, improved depression measured by 17-item Hamilton Rating Scale for Depression (HAMD-17) in adults with severe PND.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Medicine details
- Medicine name:
- zuranolone (Zurzuvae)
- SMC ID:
- SMC2862
- Indication:
For the treatment of moderate or severe postnatal depression (PND) in adults following childbirth.
- Pharmaceutical company
- Biogen
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 09 February 2026